Skip to main content

Table 1 The characteristics of the included studies

From: Prediction of sepsis mortality using metabolite biomarkers in the blood: a meta-analysis of death-related pathways and prospective validation

PubMed IDPatient no. (M/F)Comparison groups (S vs NS)Age (years, median range, or SD) (S vs NS)Follow-upSOFA (S vs NS)APACHE II (S vs NS)SAPS II (S vs NS)Matrix
PMID12562829102 (71/31)S (n = 63) vs NS (n = 39)53.8 (20–91) vs 54.9 (17–80)30 daysN/AN/AN/APlasma
PMID2367340030 (16/14)S (n = 15) vs NS (n = 15)78 (73–83) vs 79 (76–82)90 daysN/A59 (53–75) vs 76 (74–95)#N/APlasma
PMID23884467121 70/51)S (n = 90) vs NS (n = 31)56.4 ± 19.2 vs 68.8 ± 16.728 days4.3 ± 2.7 vs 7.0 ± 3.615.0 ± 7.1 vs 22.8 ± 7.8N/APlasma
PMID2388446752* (34/18)S (n = 34) vs NS (n = 18)58.9 ± 18.1 vs 58.0 ± 18.828 days4.3 ± 2.7 vs 5.0 ± 3.05.7 ± 5.8 vs 18.5 ± 7.9N/APlasma
PMID2388446761* (33/28)S (n = 36) vs NS (n = 25)54.8 ± 13.1 vs 58.7 ± 16.528 daysN/A25.9 ± 6.7 vs 33.0 ± 9.8N/APlasma
PMID243683428S (n = 4) vs NS (n = 4)61 (56–70)N/A11 (5–14)22 (16–27)N/ASerum
PMID2449813090 (39/51)S (n = 60) vs NS (n = 30)53 ± 14 vs 58 ± 1528 daysN/A23 ± 9 vs 30 ± 11N/APlasma
PMID24498130149* 68/81)S (n = 115) vs NS (n = 34)58 ± 17 vs 69 ± 1628 daysN/A15 ± 7 vs 23 ± 8N/APlasma
PMID2555324535 (30/5)S (n = 26) vs NS (n = 9)63 ± 18 vs 67 ± 1548 h10 ± 4 vs 13 ± 520 ± 8 vs 26 ± 6N/ASerum
PMID2584957135 (25/10)S (n = 20) vs NS (n = 15)54 ± 23 vs 61 ± 2128 days7 ± 4 vs 10 ± 514 ± 7 vs 22 ± 8N/ASerum
PMID25887472121 (70/51)S (n = 90) vs NS (n = 31)56.4 ± 19.2 vs 68.8 ± 16.728 days4.3 ± 2.7 vs 7.0 ± 3.615.0 ± 7.1 vs 22.8 ± 7.8N/APlasma
PMID2592879616S (n = 8) vs NS (n = 8)63 (59.8–77)N/A10.5 (7–12.5)25.5 (17.5–31.3)N/ASerum
PMID2684792220 (13/7)S (n = 9) vs NS (n = 11)61.3 ± 15.2 vs 69.9 ± 1290 days10.5 ± 1.5 vs 12.1 ± 2N/A54.8 ± 17.9 vs 61.1 ± 9.4Plasma
PMID2740694158S (n = 28) vs NS (n = 30)N/A28 daysN/AN/AN/APlasma
PMID2761498150 (27/23)S (n = 21) vs NS (n = 29)63.8 ± 0.7 vs 65.6 ± 0.57 days10.0 ± 0.8 vs 11.3 ± 0.9N/A54 ± 0.4 vs 68 ± 0.5Serum
PMID2763267222 (13/9)S (n = 13) vs NS (n = 9)60 (27–84) vs 60 (36–80)7 daysN/A22 (14–38) vs 31 (16–46)N/APlasma
PMID2834504236 (27/9)S (n = 20) vs NS (n = 16)52 ± 21.5 vs 58 ± 16.728 daysN/A17 ± 4.9 vs 22 ± 10.2N/APlasma
PMID28345042121* (70/51)S (n = 90) vs NS (n = 31)56.4 ± 19.2 vs 68.8 ± 16.728 days4.3 ± 2.7 vs 7.0 ± 3.615.0 ± 7.1 vs 22.8 ± 7.8N/APlasma
PMID3037966990 (54/36)S (n = 69) vs NS (n = 21)71.5 ± 15.4 vs 69.6 ± 12.928 days8.3 ± 3.5 vs 10.9 ± 4.023.1 ± 7.7 vs 26.1 ± 8.6N/APlasma
PMID3108856870 (40/30)S (n = 40) vs NS (n = 30)68.5 ± 0.3 vs 72.1 ± 0.424 h10.9 ± 0.1 vs 12.4 ± 0.1N/AN/ASerum
PMID3108856870* (40/30)S (n = 40) vs NS (n = 30)68.5 ± 0.3 vs 72.1 ± 0.424 h10.9 ± 0.1 vs 12.4 ± 0.1N/A55.2 ± 0.4 vs 64.3 ± 0.6Serum
  1. Abbreviations: S survivors, NS nonsurvivors, SOFA The Sequential Organ Failure Assessment, APACHE II Acute Physiology and Chronic Health Evaluation II, SAPS II Simplified Acute Physiology Score, N/A not available
  2. *Validation cohort in the same publication
  3. #APACHE III